<DOC>
	<DOCNO>NCT00101166</DOCNO>
	<brief_summary>The purpose study find effect ( good and/or bad ) new cancer vaccine patient cancer , whether safe whether help get rid cancer ( malignant melanoma ) . We want check patient 's immune system reacts , vaccine treatment .</brief_summary>
	<brief_title>Universal Granulocyte-Macrophage Colony-Stimulating Factor ( GM-CSF ) -Producing CD40L Expressing Bystander Cell Line Tumor Vaccine Melanoma</brief_title>
	<detailed_description>The vaccine make mix two kind cell : 1 ) patient 's malignant melanoma cell remove surgery process Cell Therapy Laboratory , 2 ) experimental `` bystander '' cell . All cell vaccine treat high-dose X-rays make sure none grow cause cancer . The bystander cell , call `` GM.CD40L '' , human cell genetically change . The original cell , call K562 , gene human GM-CSF CD40L insert . These change design help boost patient 's immune system well fight cancer body .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm stage IIIC stage IV melanoma Measurable disease Age 18 old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 No radiation therapy within 2 week prior first vaccine administration No chemotherapy within 4 week prior first vaccine administration No steroid therapy within 4 week prior first vaccine administration No surgery within 10 day prior first vaccine administration Patient 's write informed consent Patient 's ability comply visit schedule assessment require protocol Adequate organ function ( measure within week begin treatment ) : White blood count ( WBC ) &gt; 3,000/mm^3 absolute neutrophil count ( ANC ) &gt; 1500/mm^3 Platelets &gt; 100,000/mm^3 Hematocrit &gt; 25 % Hgb &gt; 8 g/dL Bilirubin &lt; 2.0 mg/dL Creatinine &lt; 2.0 mg/dL , creatinine clearance &gt; 60 mL/min Symptomatic untreated brain metastasis Any serious ongoing infection Current corticosteroid immunosuppressive therapy Any preexisting immunodeficiency condition ( include know HIV infection ) Pregnant lactate woman Patients reproductive age must agree use contraceptive method duration study ( *A pregnancy test obtain treatment ) ECOG performance status 2 , 3 , 4 Any second active primary cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>